Drug Trial Radar · NCT06028490
A Study of IL4Rα Monoclonal Antibody in Patients With Uncontrolled Seasonal Allergic Rhinitis.
Last checked: Nov 19, 2026Latest source record: Sep 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
90
Planned (sponsor's estimate)
Start
Sep 7, 2023
Primary completion
Nov 2023
Study completion Nov 2023
Sponsor
- Lead sponsor
- Zheng Liu ENTAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.
Conditions
- Allergic Rhinitis
Interventions
GR1802 injection-1Biological
subcutaneous,dose\*1
GR1802 injection-2Biological
subcutaneous,dose\*2
PlaceboBiological
subcutaneous,dose\*2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average change from baseline in daily retrospective total nasal symptom score (rTNSS) during treatment period.Time frame: week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tongji Hosptial affiliated to Tongji Medical college of Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.